Chlormezanone
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 40.5 hours |
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Chlormezanone (marketed under the
Its use was discontinued in many countries in 1996 due to rare but serious cases of toxic epidermal necrolysis.[2]
Synthesis
References
- ISBN 978-1-349-13937-8.
- S2CID 46796285.
- ^ US 3082209, Surrey AR, "4-metathiazanone derivatives and their preparation", issued 1958, assigned to Sterling Drug Inc.
- .
Further reading
- Wollina U, Hipler UC, Seeling A, Oelschlager H (2005). "Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro". Skin Pharmacology and Physiology. 18 (3): 132–138. S2CID 36642315.
- Seeling A, Oelschläger H, Rothley D (April 2000). "[Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone]". Die Pharmazie. 55 (4): 293–296. PMID 10798243.
- Oelschläger H, Klinger W, Rothley D, Seeling A, Bockhard H, Hofmann B, et al. (September 1998). "[Cleavage and biotransformation of the central muscle relaxant chlormezanone]". Die Pharmazie. 53 (9): 620–624. PMID 9770210.
- Gautier V, Vinçon G, Demotes-Mainard F, Albin H (1990). "[Pharmacokinetics of chlormezanone in healthy volunteers]". Therapie. 45 (4): 315–319. PMID 2399514.